Academic Honors and Prices
- Health Young Physician Leaders (YPL) programme of the Interacademy Partnership (IAP), Berlin, Germany – nominated by the Accademia Nazionale dei Lincei
- Scholarship of the European Society of Cardiology (ESC) for an Executive MSc in Health Economics, Outcomes and Management in Cardiovascular Sciences 2016-2018 at the London School of Economics, London, UK
- 2014: William Harvey Award, Italian Society of Cardiology (SIC)
- 2014: Best Abstract Award, Joint Annual Meeting of the Swiss Society of Cardiology (SGK-SSC)
- 2014: Fellow of the European Society of Cardiology (FESC)
- 2012: Finalist of the Linnemeier Spirit of Interventional Cardiology Young Investigator Award, Transcatheter Cardiovascular Therapeutics (TCT), Cardiovascular Research Foundation
- 2011: Research Grant, European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC)
- 2010: GISE Prize for Best Scientific Contribution, 31st Congress of the Italian Society of Interventional Cardiology (SICI-GISE)
Prof Stefanini was born in Rome, where he studied Medicine and finalized his training in Cardiology at Sapienza University. In 2010 he moved to Bern University Hospital for a clinical research fellowship supported by a grant of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). In 2012 he was awarded a competitive 3-year research support under the Special Program University Medicine program (SPUM) of the Swiss National Science Foundation, supporting his position as researcher and interventional cardiologist at Bern University Hospital.
In 2015, Prof Stefanini moved to Milan where he has a position as Associate Professor of Cardiology at Humanitas University and works as Clinical and Interventional Cardiologist at IRCCS Humanitas Research Hospital and Humanitas S. Pio X Hospital. He also serves as head of clinical research of the Cardio Center of Humanitas Research Hospital
Prof Stefanini’s main research area is minimally-invasive treatment strategies for coronary artery disease, with a specific focus on devices for coronary revascularization. During the last 10 years, he has been involved in the design, conduct, data-analysis, and successful publication of randomized trials, observational studies, and meta-analyses. He has authored several relevant articles in major medical journals including the New England Journal of Medicine and the Lancet. His research is currently funded by competitive grants obtained from the Italian Ministry of Health (Ricerca Finalizzata), the Italian Medicines Agency (AIFA Ricerca Indipendente), and the Italian Ministry of Education (PRIN). Prof Stefanini is actively contributing to the European Society of Cardiology (ESC), has been a member of the ESC Task Force for the Guidelines on Myocardial Revascularization, of the ESC Task Force for the evaluation of coronary artery stents, and of the ESC Task Force for the Diagnosis and Management of CV Disease in the Context of the COVID-19 Pandemic. He has also chaired the EAPCI Consensus Document on Myocardial Revascularization Failure. He is currently co-chair of the Scientific Documents Committee of the EAPCI and was recently appointed Editor-in-Chief of the Italian Journal of Invasive Cardiology (GICI).
- Stefanini GG, et al. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J 2021; 42:4683-4693
- Chiarito M, …and Stefanini GG. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis. Lancet 2020, 395:1487–95
- Stefanini GG, et al. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet 2013, 382:1879-88
- Stefanini GG, Holmes DR Jr. Drug-Eluting Coronary Artery Stents. N Eng J Med 2013; 368:254-65
- Stefanini GG, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011; 378:1940-8